ArticleScientific reports2025
Epidemiology and risk factors for cerebral venous sinus thrombosis: insights from leading centres in the i-RegVeD registry, India.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Cerebral venous thrombosis-related stroke in India: Clinical patterns, risk factors, and outcomes from the hospital-based stroke registry programme.The Indian journal of medical research · 2026Article
- Cerebral Veins and Dural Sinuses Thrombosis: Data from a Monocentric Cohort Study of 55 Romanian Patients.Life (Basel, Switzerland) · 2026Article
- Previous Cerebral Venous Sinus Thrombosis in Pregnancy: Clinical Challenges and Outcomes - A Case Report.International journal of women's health · 2026Article
- Risk factors for cerebral venous sinus thrombosis in Xinjiang, China: a single-center case-control study with a focus on high-altitude exposure.American journal of translational research · 2026Article
- Article
Corrections and comments
- Erratum issued
Authors and funding
5 authors.
Funding
Abstract
CVST is a rare cerebrovascular condition commonly associated with young adults and females. The primary aim of this study was to identify key risk factors associated with CVST and assess the outcomes of participants with CVST. This is an ongoing multicenter hospital-based study conducted from July 2022 to October 2023. A total of 152 CVST participants were selected from seven participating sites. The diagnosis of CVST was confirmed via a CT scan or MRI/MRV. Sociodemographic variables, i.e., lifestyle variables, type of objective testing, clinical presentations, risk factors and hospital outcomes, were recorded. Logistic regression was applied to identify risks associated with CVST and was adjusted for confounders such as age, sex, and comorbidity. The median (range) age of the CVST patients was 29 (0-69) years, with a significantly higher proportion of the registered CVST participants being males than females (63.8% vs 36.2%, P < 0.001). The peak frequency of CVST participants was recorded among those aged 21-30 years, accounting for 32.9% of the participants. The most common clinical manifestation was vomiting in 39.5% of the participants, followed by headache in 29.6% of the participants. The study identified young adults to be at increased risk of CVST (OR 0.28; 95% CI 0.18-0.42; P = < 0.001) and alcohol consumption with higher incident of CVST than never used alcohol (OR 1.95; 95% CI 1.17-3.23; P = 0.010) after adjusted for confounders. Study reported around 97% of participants were discharged after treatment, and mortality was reported in 3.2% of participants. CVST was strongly associated with males and young adults in this study, raising serious concerns. Alcohol intake was associated with a greater risk of CVST. The findings of this study could inform the development of region-specific protocols and targeted public health efforts, ultimately enhancing patient outcomes and reducing CVST-related mortality and morbidity in India.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.